Condensed Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Pfizer collaboration revenue		$ 25,172	$ 0	$ 54,681	$ 0
Total revenues		77,902	0	118,965	33,333
Collaboration expense to Pfizer		8,565	0	13,826	0
Research and development		26,280	40,521	57,160	84,707
Selling, general and administrative	[1]	58,781	31,316	119,993	54,144
Total operating costs and expenses		96,248	71,837	194,633	138,851
Loss from operations		(18,346)	(71,837)	(75,668)	(105,518)
Interest expense	[2]	3,494	2,115	6,999	4,299
Interest income		(100)	(38)	(178)	(146)
Foreign exchange gain		0	(6,718)	0	(10,287)
Loss before income taxes		(21,740)	(67,196)	(82,489)	(99,384)
Income tax (benefit) expense		(149)	(134)	762	538
Net loss		$ (21,591)	$ (67,062)	$ (83,251)	$ (99,922)
Net loss per common share - basic (in USD per share)		$ (0.23)	$ (0.75)	$ (0.90)	$ (1.12)
Net loss per common share - diluted (in USD per share)		$ (0.23)	$ (0.75)	$ (0.90)	$ (1.12)
Weighted average common shares outstanding - basic (in shares)		92,355,150	89,744,142	92,019,987	89,523,389
Weighted average common shares outstanding - diluted (in shares)		92,355,150	89,744,142	92,019,987	89,523,389
Product revenue, net
Revenues		$ 21,063	$ 0	$ 32,617	$ 0
Cost of revenue		2,622	0	3,654	0
Richter license and milestone revenue
Revenues		$ 31,667	$ 0	$ 31,667	$ 33,333

[1] Includes $1,173 and $2,447 of related party expense (inclusive of third-party pass-through costs) for the three and six months ended September 30, 2021, respectively. Includes $1,291 and $1,405 of related party expense (inclusive of third-party pass-through costs) for the three and six months ended September 30, 2020, respectively (see Note 5).

[2] Includes $2,885 and $5,789 of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the three and six months ended September 30, 2021, respectively. Includes $2,115 and $4,299 of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the three and six months ended September 30, 2020, respectively (see Note 5).